For example, Grem1 expression correlates with progression-free survival in pancreatic neuroendocrine tumors [49] and colorectal cancer [50], but it is an indicator of poor progression-free survival in cervical cancer [51]. This evidence concerns the gene GREM1 and colorectal cancer.